-
×
Mrs. Burcu Avci
(Team lead Medical Support)
Mrs. Burcu Avci
(Team lead Medical Support)Contact me without obligation and free
of charge by phone
(mo - fr: 8 a.m. - 4 p.m.)Call now
+44 800 06 68 698Year: 2021
The EFFECT study underlines the efficacy of hypoglossal nerve stimulation in terms of severity and symptomatology of obstructive sleep apnoea (OSA). The methodologically convincing study is an important addition to the evidence base for Inspire therapy.
Predictors of post-admission upper airway stimulation in the adherent registry
Year: 2018
Author(s): Heiser C, Steffen A, Boon M et al.
Conclusion: In a large international multicentre registry, upper airway stimulation is an effective treatment option with high patient satisfaction and low adverse events. Older age and lower BMI are predictors of treatment response.
Upper airway stimulation for obstructive sleep apnoea: 5-year results
Year: 2018
Author(s): Woodsen BT, Kingman P, Strohl P et al.
Conclusion: Over 5 years of use, upper airway stimulation (UAS) results in consistent and sustained improvement in fatigue, quality of life and respiratory endpoints. Serious adverse events are rare. UAS is a minimally invasive surgical OSA treatment with a long-term benefit for sufferers of moderate to severe obstructive sleep apnoea (OAS) following CPAP intolerance or failure.
One-year results of Inspire airway stimulation in routine care in Germany
Year: 2018
Author(s): Steffen A, Sommer JU, Hofauer B et al.
Conclusion: Upper airway stimulation (UAS) is a safe and effective treatment option for sufferers of obstructive sleep apnoea (OAS) in routine clinical care, according to the study results.
Inspire STAR study: subjective results after 48 months
Year: 2017
Author(s): Gillespie MB, Soose RJ, Woodsen BT et al.
Conclusion: Upper airway stimulation showed a sustained benefit in patient-reported outcomes (Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, snoring) in selected patients with moderate to severe obstructive sleep apnoea after 48 months.
Year: 2015
Author(s): Strollo PJ Jr, Gillespie MB, Scoose RJ et al; Stimulation Therapy for Apnea Reduction (STAR) Trial Group.
Conclusion: Upper airway stimulation via the hypoglossal nerve resulted in sustained improvement in airway stability during sleep and improved patient-reported sleep-related quality of life (Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire) without increasing stimulation intensity or tongue injury during an 18-month follow-up.
Long-term results after three years: STAR Study
Year: 2015
Author(s): Woodsen BT, Scoose RJ, Gillespie MB et al. on Behalf of STAR Trial Investigators
Conclusion: Objective respiratory endpoints and subjective quality of life improvements under upper airway stimulation are constant over 3 years. Adverse events are rare. Upper airway stimulation (UAS) is a successful long-term treatment for patients with moderate to severe obstructive sleep apnoea (OAS).
Clinical consequences and economic costs of untreated obstructive sleep apnoea
Year: 2015
Author(s): Knauert M, Naik S, Gillespie MB et al.
Conclusion: Undiagnosed and untreated obstructive sleep apnoea can lead to abnormal physiology and can have severe consequences such as cardiovascular disease, stroke, metabolic disease, excessive daytime sleepiness, workplace errors, road traffic accidents and death. These consequences result in a significant economic burden. Both the health and social consequences and their costs can be reduced by diagnosing and treating sleep apnoea.
Results of the ADHERE registry on upper airway stimulation and predictors of treatment success
Year: 2019
Author(s): Thaler E, Schwab R, Maurer J et al.
Conclusion: In a multicentre study, upper airway stimulation (UAS) achieved significant improvement in subjective and objective endpoints. This analysis shows that the therapy effect is lasting and the therapy adherence is high.
Further interesting publications on hypoglossal nerve stimulation can be found here: